Voss H, Pohle H D, Museteanu C
Zentralbl Bakteriol Orig A. 1977 Feb;237(1):1-34.
On the base of plaque inhibition tests in at least three virus-host-systems and successful treatment of mice with experimentally induced yellow fever encephalitis a well known sulphated glycosaminoglycan (GAGPS) "L5" was used as therapeutic agent in cases of zoster infection in man. The material was applied as 1% solution in water continuously on lint and rewettet for several days until nearly complete healing was achieved. The clinical course of 18 patients of former years (12 women, 6 men) was compared with 26 cases (19 women, 7 men) treated additionally with the new substance. All of them were carefully observed in the Rudolf-Virchow-Hospital in Berlin. Besides of registrating data as age and sex of the patients and the seasonal distribution of cases the course of illness was analyzed. The mean duration before admission to the hopsital was 4,9 days in the control group and 7,2 days in the L5-patients. Signs of organ diseases possibly acting as trigger mechanism for the remanifestation of the zoster were nearly twice in number in L5 cases than in the controls. Despite of this unfavorable stiutation the main parameters showed a clear tendency to return earlier to normal values in the GAGPS group. The fever was shortened. The blood lymphocytes normalized better with mean absolute values of 2400 in the L5-group and 3029 per m(3) in the control cases. The fall of the cell number in the liquor cerebrospinalis was more rapidly in the GAGPS treatment. The mean stay in the hospital was 33,2 days in L5 cases and 44,6 days in control patients respectively in the main group of age between 60 and 80 years. One death in the GAGPS group corresponded to four in the control group. In the local skin area the edema disappeared rapidly with beginning of treatment. Confluent vesicles flattened within 24 to 48 hours and no further efflorescences were seen. Pain diminished in few days. The good results justify continued trials.
在至少三种病毒-宿主系统的噬斑抑制试验以及用实验性诱导的黄热病脑炎成功治疗小鼠的基础上，一种著名的硫酸化糖胺聚糖（GAGPS）“L5”被用作人类带状疱疹感染病例的治疗药物。该物质以1%的水溶液持续涂抹在纱布上，并多次重新湿润，直至伤口几乎完全愈合。将前几年的18例患者（12名女性，6名男性）的临床病程与另外26例（19名女性，7名男性）使用该新物质治疗的病例进行了比较。所有患者均在柏林的鲁道夫·菲尔绍医院接受了仔细观察。除了记录患者的年龄、性别以及病例的季节分布等数据外，还对疾病进程进行了分析。对照组患者入院前的平均病程为4.9天，而使用L5治疗的患者为7.2天。可能作为带状疱疹复发触发机制的器官疾病体征，在使用L5治疗的病例中几乎是对照组的两倍。尽管存在这种不利情况，但主要参数显示，GAGPS组明显更倾向于更早恢复到正常水平。发热时间缩短。血液淋巴细胞恢复正常的情况更好，L5组的平均绝对值为每立方毫米2400个，对照组为每立方毫米3029个。在GAGPS治疗中，脑脊液中的细胞数量下降得更快。在主要年龄组60至80岁中，使用L5治疗的患者平均住院时间为33.2天，对照组患者为44.6天。GAGPS组有1例死亡，对照组有4例死亡。在局部皮肤区域，治疗开始后水肿迅速消失。融合性水疱在24至48小时内变平，未见进一步的皮疹。疼痛在几天内减轻。这些良好的结果证明继续试验是合理的。
